VANGUARD GROUP INC - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 102 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.9%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$3,898,514
+115.1%
2,107,305
+29.0%
0.00%
Q4 2022$1,812,827
-52.3%
1,633,178
+0.5%
0.00%
Q3 2022$3,804,000
-21.7%
1,625,857
+1.4%
0.00%
Q2 2022$4,857,000
-55.7%
1,602,974
-0.7%
0.00%
Q1 2022$10,956,000
-17.6%
1,613,505
+1.3%
0.00%
Q4 2021$13,294,000
+24.0%
1,592,032
+10.3%
0.00%
Q3 2021$10,725,000
+12.1%
1,443,429
+2.6%
0.00%
Q2 2021$9,566,000
-31.6%
1,406,825
+3.4%
0.00%
Q1 2021$13,976,000
+121.6%
1,360,765
+51.0%
0.00%
Q4 2020$6,307,000
-14.4%
901,060
-0.2%
0.00%
Q3 2020$7,368,000
+8.6%
902,992
-8.1%
0.00%
Q2 2020$6,782,000
+41.1%
982,863
-2.9%
0.00%
Q1 2020$4,806,000
-41.4%
1,011,825
+7.7%
0.00%
Q4 2019$8,202,000
+184.9%
939,538
+8.7%
0.00%
Q3 2019$2,879,000
-27.3%
864,688
+8.1%
0.00%
Q2 2019$3,961,000
+4.5%
800,150
+30.8%
0.00%
Q1 2019$3,792,000
+135.5%
611,610
+28.0%
0.00%
Q4 2018$1,610,000
-68.1%
477,871
-38.4%
0.00%
Q3 2018$5,045,000
-10.3%
776,016
+5.7%
0.00%
Q2 2018$5,623,000
-58.5%
734,071
+21.1%
0.00%
-100.0%
Q1 2018$13,545,000
+60.2%
606,071
-8.6%
0.00%
Q4 2017$8,453,000
-6.3%
662,932
+14.5%
0.00%
Q3 2017$9,024,000
+152.2%
579,160
+127.1%
0.00%
Q2 2017$3,578,000
+42.8%
255,060
+123.8%
0.00%
Q1 2017$2,506,000113,9640.00%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
TRV GP II, LLC 572,829$1,340,000100.00%
TRV GP III, LLC 1,148,780$2,688,0001.17%
COWEN AND COMPANY, LLC 3,647,430$8,535,0000.82%
Octagon Capital Advisors LP 1,400,000$3,276,0000.56%
Deep Track Capital, LP 4,259,653$9,968,0000.46%
PFM Health Sciences, LP 4,094,488$9,581,0000.35%
RTW INVESTMENTS, LP 5,106,341$11,949,0000.28%
Omega Fund Management, LLC 275,513$645,0000.24%
Monarch Partners Asset Management LLC 228,370$534,0000.16%
Orbimed Advisors 2,928,900$6,854,0000.13%
View complete list of JOUNCE THERAPEUTICS INC shareholders